Oportun to Report Fourth Quarter 2022 Financial Results on

Oportun to Report Fourth Quarter 2022 Financial Results on

SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven fintech and digital banking platform, will release......

Superior Group of Companies to Announce Fourth Quarter and

Superior Group of Companies to Announce Fourth Quarter and

SEMINOLE, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”) today announced that it intends to......

Avid Bioservices to Report Financial Results for Third

Avid Bioservices to Report Financial Results for Third

TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing......

Amy Somerville Ushered in as CEO of SUCCESS Enterprises To

Amy Somerville Ushered in as CEO of SUCCESS Enterprises To

Somerville brings extensive leadership experience, media prowess and proven track record of changing lives......

Hyperfine, Inc. to Announce Fourth Quarter and Full Year

Hyperfine, Inc. to Announce Fourth Quarter and Full Year

GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop®......

Bath & Body Works Announces Appointment of Thomas J. Kuhn

Bath & Body Works Announces Appointment of Thomas J. Kuhn

Experienced Financial and Governance Advisor Brings 35 Years of Experience to Board......

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA

SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation......

Himax Technologies, Inc. to Attend 26th Credit Suisse Asian

Himax Technologies, Inc. to Attend 26th Credit Suisse Asian

TAINAN, Taiwan, March 06, 2023 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless......

Additional Data on Lumos OraGrowtH Trials Presented

Additional Data on Lumos OraGrowtH Trials Presented

Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics......

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG......

  • 1
  • ...
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...
  • 38
  • menu
    menu